MDR 3.45% 30.0¢ medadvisor limited

Hi Orange7575, Thanks for the well wishes but unfortunately back...

  1. 51 Posts.
    Hi Orange7575,

    Thanks for the well wishes but unfortunately back to work already. Lol

    Pharmacies pay $100 per month in subscription fee, let's put it into perspective, if a pharmacy uses one of the other providers for SMS services, the monthly fee is around $40-50 however the pharmacy will need to pay for each individual SMS at a rate of 20-30cents. So as you scale your patient numbers, there will be a cost incurred, whereas a flat $100 per month fee for MDR allows a pharmacy to scale without additional cost. However, I believe that MDR gets significant revenue from the drug manufacturers to include logos and CMIs and instructional material for their products.

    Patient compliance is the key, any medication which has a silent effect on your health usually does not have a great compliance level, meds for blood pressure, diabetes, asthma prevention, cholesterol, patients should take it everyday, but when they don't, there usually is no immediate noticeable harm on their health, hence the failure to comply. For that reason and from a pharmacy point of view, compliance level is usually around 60-70%. Improving compliance means;
    1. Better health outcome for patient
    2. More dispenses per medication per patient per pharmacy
    3. More products used from a manufacturer's point of view
    4. Less adverse events and hospital admissions associated with non-compliance hence less government expenditure
    So all parties involved are set to benefit from MDR

 
watchlist Created with Sketch. Add MDR (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
0.010(3.45%)
Mkt cap ! $215.0M
Open High Low Value Volume
29.0¢ 30.0¢ 27.5¢ $254.8K 889.6K

Buyers (Bids)

No. Vol. Price($)
2 39326 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 2917 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.